- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01349907
Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898) (ADDRESS-98)
February 7, 2022 updated by: Organon and Co
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder
This study will investigate the safety and tolerability of a flexible dosing regimen of asenapine for the long-term treatment of manic or mixed episodes associated with bipolar disorder I in children and adolescents who completed study P06107.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
322
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completed study P06107 and demonstrated acceptable degree of compliance with medication, visits and other study requirements
- Must be male or a female who is not of childbearing potential and is not sexually active or is using a medically accepted method of contraception; or female who is not pregnant, or not lactating.
- Must have a caregiver or responsible person living with the participant who agrees to provide support to ensure compliance with treatment, visits, and protocol procedures
Exclusion Criteria:
- Positive pregnancy test or intention to become pregnant during the study
- At imminent risk of self-harm or harm to others
- Under involuntary inpatient commitment
- Known serological evidence of human immunodeficiency virus (HIV) antibody
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Asenapine/Asenapine
Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7.
After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
|
One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days.
Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose.
Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose.
The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion.
Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
Other Names:
For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances.
For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed.
Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
|
EXPERIMENTAL: Placebo/Asenapine
Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7.
After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
|
One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days.
Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose.
Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose.
The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion.
Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
Other Names:
For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances.
For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed.
Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced Clinical or Laboratory Adverse Events
Time Frame: Baseline (Day 1) to 30 days after the last dose of study drug (up to approximately 54 weeks)
|
A clinical or laboratory adverse event is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.
|
Baseline (Day 1) to 30 days after the last dose of study drug (up to approximately 54 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Young Mania Rating Scale (Y-MRS) Total Score
Time Frame: Baseline, Day 182 and Day 350
|
The Y-MRS assesses the severity of manic episodes by assigning a severity rating to each of 11 items (Elevated mood, Increased motor activity-energy, Sexual interest, Sleep, Irritability, Speech, Language-thought disorder, Thought content, Disruptive-aggressive behavior, Appearance, Insight).
Seven of the 11 items are rated on a scale of 0-4, and 4 of the items are rated on a scale of 0-8.
The Y-MRS total score, observed cases (OC), the assessment closest to the scheduled assessment day within the allowed window, is the sum of the ratings for the 11 individual items, and can range from 0-60, with higher scores indicating greater severity of symptoms.
Improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline, Day 182 and Day 350
|
Percentage of Participants Who Were Y-MRS Total Score Remitters (Y-MRS ≤12)
Time Frame: Up to Day 350
|
The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes.
The Y-MRS total score, OC for each participant is the sum of the ratings for the 11 individual items, and can range from 0-60, with higher scores indicating greater severity of symptoms.
A remitter is a participant with a Y-MRS total score of 12 or lower.
|
Up to Day 350
|
Percentage of Participants Who Were Y-MRS Total Score Responders
Time Frame: Up to Day 350
|
The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes.
The Y-MRS total score, OC for each participant is the sum of the ratings for the 11 individual items, and can range from 0-60, with higher scores indicating greater severity of symptoms.
A Y-MRS responder experiences a 50% or more decrease from baseline in Y-MRS total score.
|
Up to Day 350
|
Time to First Total Y-MRS 50% Response
Time Frame: Up to Day 350
|
The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes.
The Y-MRS total score, OC for each participant is the sum of the ratings for the 11 individual items, ranging from 0-60, with higher scores indicating more severe symptoms.
The time to 50% response is the number of days on treatment to achieve a 50% decrease from baseline in Y-MRS total score.
|
Up to Day 350
|
Time to Failure to Maintain Response in Y-MRS Total Score
Time Frame: Up to Day 350
|
The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes.
The Y-MRS total score, OC for each participant is the sum of the ratings for the 11 individual items, ranging from 0-60, with higher scores indicating more severe symptoms.
The time to failure is the number of days from first achieving a 50% or more decrease from baseline in Y-MRS total score to the first subsequent day of a less than 50% decrease from baseline in Y-MRS total score.
|
Up to Day 350
|
Change From Baseline in Clinical Global Impression Scale for Assessing Overall Bipolar Illness (CGI-BP Overall)
Time Frame: Baseline, Day 182 and Day 350
|
The CGI-BP overall is a single value score OC for assessing overall bipolar illness, recorded on a 7-point scale ranging from 1 for normal/not ill, to 7 for very severely ill.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline, Day 182 and Day 350
|
Change From Baseline in Clinical Global Impression Scale for Assessing Depression (CGI-BP Depression)
Time Frame: Baseline, Day 182 and Day 350
|
The CGI-BP depression is a single value score OC for assessing depression, recorded on a 7-point scale ranging from 1 for normal/not ill, to 7 for very severely ill.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline, Day 182 and Day 350
|
Change From Baseline in Clinical Global Impression Scale for Assessing Mania (CGI-BP Mania)
Time Frame: Baseline, Day 182 and Day 350
|
The CGI-BP mania is a single value score OC for assessing mania, recorded on a 7-point scale ranging from 1 for normal/not ill, to 7 for very severely ill.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline, Day 182 and Day 350
|
Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Time Frame: Baseline, Day 182 and Day 350
|
The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children.
Fourteen of the 17 items are rated on a scale of 1-7, and 3 of the items are rated on a scale of 1-5, with higher scores indicating greater severity of symptoms.
The CDRS-R total score, OC for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms.
Improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline, Day 182 and Day 350
|
Percentage of CDRS-R Responders
Time Frame: Up to Day 350
|
The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children.
The CDRS-R total score, OC for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms.
A CDRS-R responder experiences a 50% or more decrease from baseline in CDRS-R total score.
|
Up to Day 350
|
Percentage of Participants With Emergent Depression Based on CDRS-R
Time Frame: Up to Day 350
|
The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children.
The CDRS-R total score, OC for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms.
Participants with a CDRS-R score of 40 or greater (whose baseline CDRS-R is less than 40) exhibit emergent depression, which is a strong indicator of the presence or potential for a major depressive disorder.
|
Up to Day 350
|
Change From Baseline in Children's Global Assessment Scale (CGAS)
Time Frame: Baseline, Day 182 and Day 350
|
CGAS is a scale with a possible range of 1 to 100, measuring psychological, social, and school functioning in children.
Minimum scores, OC range from 1-10, representing the need for constant supervision (worse result) to maximum scores of 91-100, representing superior functioning (better result).
An improvement in function is represented by a change from baseline value that is positive.
|
Baseline, Day 182 and Day 350
|
Percentage of Participants With a CGAS Score of Equal or Greater Than 70
Time Frame: Up to Day 350
|
CGAS is a scale with a possible range of 1 to 100, measuring psychological, social, and school functioning in children.
Minimum scores, OC range from 1-10, representing the need for constant supervision (worse result) to maximum scores of 91-100, representing superior functioning (better result).
The percentage of participants with a score of 70 or greater, representing normal to superior social functioning, is shown.
|
Up to Day 350
|
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaires (PQ-LES-Q) Total Score
Time Frame: Baseline, Day 182 and Day 350
|
PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents.
The participant rates 15 items reflecting quality of life from the previous week on a scale of 1=very poor to 5=very good.
Items 1-14 assess specific areas (e.g., health, mood or feelings); item 15 is a global assessment of overall quality of life.
The PQ-LES-Q total score for each participant, OC is the sum of the rating assigned to each of the first 14 items, and ranges from 14 to 70, with a higher score indicating better quality of life.
An improvement in quality of life is represented by change from baseline values that are positive.
|
Baseline, Day 182 and Day 350
|
Change From Baseline in PQ-LES-Q Overall Score
Time Frame: Baseline, Day 182 and Day 350
|
PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents.
The participant rates 15 items reflecting quality of life from the previous week.
Item 15, the PQ-LES-Q overall score, observed OC, is a global assessment of overall quality of life, and ranges from 1 to 5, with a higher score indicating better quality of life.
An improvement in quality of life is represented by change from baseline values that are positive.
|
Baseline, Day 182 and Day 350
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Findling RL, Landbloom RL, Szegedi A, Koppenhaver J, Braat S, Zhu Q, Mackle M, Chang K, Mathews M. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. J Am Acad Child Adolesc Psychiatry. 2015 Dec;54(12):1032-41. doi: 10.1016/j.jaac.2015.09.007. Epub 2015 Oct 24.
- Findling RL, Landbloom RL, Mackle M, Wu X, Snow-Adami L, Chang K, Durgam S. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Paediatr Drugs. 2016 Oct;18(5):367-78. doi: 10.1007/s40272-016-0184-2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 16, 2011
Primary Completion (ACTUAL)
September 5, 2014
Study Completion (ACTUAL)
September 5, 2014
Study Registration Dates
First Submitted
May 5, 2011
First Submitted That Met QC Criteria
May 5, 2011
First Posted (ESTIMATE)
May 9, 2011
Study Record Updates
Last Update Posted (ACTUAL)
February 9, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P05898
- MK-8274-022 (OTHER: Merck Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
Clinical Trials on Asenapine
-
Organon and CoCompleted
-
Lori Davis, MDMerck Sharp & Dohme LLC; Forest LaboratoriesCompletedAn Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress DisorderPosttraumatic Stress DisorderUnited States
-
Organon and CoCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
Organon and CoCompleted
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Completed
-
Organon and CoCompleted